These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 28574826)

  • 1. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
    Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
    Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simiao Qingwen Baidu decoction inhibits Epstein-Barr virus-induced B lymphoproliferative disease and lytic viral replication.
    Yang X; Liu L; Zhang H; Sun X; Yan Y; Ran R
    Pharm Biol; 2021 Dec; 59(1):741-747. PubMed ID: 34155950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
    Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
    Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
    Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
    Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
    Anderson AG; Gaffy CB; Weseli JR; Gorres KL
    Viruses; 2019 May; 11(5):. PubMed ID: 31108875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
    Jiang L; Zhang W; Li W; Ling C; Jiang M
    Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC Controls the Epstein-Barr Virus Lytic Switch.
    Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
    Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
    Kalla M; Hammerschmidt W
    Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
    Tanner JE; Menezes J
    Blood; 1994 Dec; 84(11):3956-64. PubMed ID: 7949151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
    Tanner JE; Alfieri C
    Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaetocin reactivates the lytic replication of Epstein-Barr virus from latency via reactive oxygen species.
    Zhang S; Yin J; Zhong J
    Sci China Life Sci; 2017 Jan; 60(1):66-71. PubMed ID: 28063010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
    Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
    Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD; Brooks JB
    Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
    Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
    Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.